Paper Details

  1. Home
  2. Paper Details

Comparison of the effects of high dose Estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study no. 30865.

Author: De PauwM, FossaS, KurthK H, NewlingD W, SylvesterR, TunnU

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

High-dose Estramustine phosphate and Mitomycin C were not effective in treating hormone-escaped advanced progressive prostate cancer. Both treatments resulted in rapid disease progression and significant toxicity.
Paper Details　
Original Abstract of the Article :
Patients with hormone escaped advanced progressive prostate cancer were randomized either to receive either high-dose Estramustine phosphate orally or Mitomycin C by i.v. injection every 6 weeks until signs of progression or death supervened. Patients on both arms progressed rapidly, with a median t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0960-0760(90)90452-q

データ提供：米国国立医学図書館（NLM）

Facing the Challenge of Hormone-Independent Prostate Cancer: A Comparative Study of Estramustine Phosphate and Mitomycin C

Prostate cancer, a significant health concern for men, can become resistant to hormonal therapies, leading to a more aggressive form of the disease. This study explores the effectiveness of two different treatments, high-dose Estramustine phosphate and Mitomycin C, in patients with hormone-independent advanced prostate cancer. The researchers conducted a randomized trial involving patients with progressive, advanced prostate cancer. The results revealed that both treatments led to rapid disease progression, with a median time to progression of 5 months and a median survival of only 10 months. The study highlights the need for further research into more effective treatment strategies for this challenging form of cancer.

Navigating the Complex Landscape of Hormone-Independent Prostate Cancer

This study underscores the complex and challenging nature of hormone-independent prostate cancer. The findings highlight the limited effectiveness of high-dose Estramustine phosphate and Mitomycin C in delaying disease progression and extending survival. The researchers' observations emphasize the urgent need for novel therapeutic approaches to effectively manage this aggressive form of cancer.

A Search for Better Treatment Options: The Importance of Research

The study's results serve as a reminder of the importance of ongoing research and development of new treatments for hormone-independent prostate cancer. The limited effectiveness of existing therapies underscores the need for continued exploration of innovative approaches, such as targeted therapies and immunotherapies, to improve patient outcomes.

Dr.Camel's Conclusion

This study provides valuable insights into the challenges of treating hormone-independent prostate cancer. The limited effectiveness of existing therapies emphasizes the urgent need for further research into more effective and targeted treatments. It's a reminder that the fight against cancer is an ongoing journey, requiring continuous innovation and collaboration to improve patient outcomes.

Date :
  1. Date Completed 1991-03-27
  2. Date Revised 2019-08-28
Further Info :

Pubmed ID

2126739

DOI: Digital Object Identifier

10.1016/0960-0760(90)90452-q

Related Literature

Article Analysis
・Effects of estramustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.